同位素稀释-气相色谱串联质谱法测定啤酒中4种亚硝胺类化合物

目的 建立啤酒中4种N-亚硝胺类化合物（N-亚硝基二甲胺、N-亚硝基二乙胺、N-亚硝基二丙胺、N-亚硝基二苯胺）的同位素稀释固相萃取-气相色谱串联质谱测定方法。 方法 样品经活性炭固相萃取小柱富集、二氯甲烷洗脱,洗脱液经氮吹浓缩定容后,采用INNOWAX毛细管色谱柱分离,多反应监测（MRM）模式检测,同位素稀释内标法定量。 结果 各物质在5 μg/L~200 μg/L范围内线性关系良好,相关系数均大于0.9995。方法的检出限为0.03-0.10 μg/L,定量限为0.10~0.33 μg/L。不同水平的加标回收率为72.1%~100.3%,相对标准偏差为1.5%~9.5%（n=6）。 结论 该方法操作简单,灵敏度和准确度高,适用于啤酒中4种N-亚硝胺类化合物的测定。     

串联质谱技术在脂肪酸氧化代谢病诊断中的应用研究

目的探讨利用串联质谱技术检测干血滤纸片中酰基肉碱水平,诊断脂肪酸氧化代谢病。方法对象为2941例临床遗传性代谢病高危儿童,利用串联质谱技术检测患儿干血滤纸片中酰基肉碱水平,结合临床资料和常规生化结果,进行脂肪酸氧化代谢病诊断。结果诊断了14例脂肪酸氧化代谢病(0.5%),其中肉碱棕榈酰转移酶Ⅰ缺乏症1例,肉碱棕榈酰转移酶Ⅱ缺乏症1例,短链酰基辅酶A脱氢酶缺乏症1例,中链酰基辅酶A脱氢酶缺乏症7例,极长链酰基辅酶A脱氢酶缺乏症2例,多种酰基辅酶A脱氢酶缺乏症2例。结论通过串联质谱技术检测干血滤纸片中酰基肉碱水平,可对部分脂肪酸氧化代谢病进行诊断。     

用二核苷酸简单串联重复顺序多态位点进行中国人个体鉴别

为建立二核苷酸简单串联重复顺序（ＳＴＲ）多态位点个体鉴别技术系统，应用６个位于不同染色体呈共显性传递的二核苷酸ＳＴＥ多态位点进行中国汉族人个体鉴别研究，这６个位点是Ｄ１Ｓ１０３、Ｄ４Ｓ１７５、Ｄ５Ｓ１０７、Ｄ１９Ｓ４９、Ｄ６Ｓ８９及Ｄ９Ｓ５８。结果显示：（１）６个ＳＴＲ位点基因型数１４～３９个，等位片段数０～２０个；（２）杂合度观察值及估测值分别为０．６５～０．９１及０．６３～０．９３．多态信息含量０．５９～０．９０；（３）６个位点均符合Ｈａｒｄｙ－Ｗｅｉｎｂｅｒｇ平衡；（４）６个位点１５次配对分析中，未见非随机关联；（５）６个位点的亲子关系排除概率０．９９；（６）普通群体中两个无亲缘关系随机个体间６个位点基因型完全一致的概率在１．７×１０－１２～９．２×１０－３３间。结果表明，应用这六个二核苷酸ＳＴＲ位点适于亦足以在中国汉族人中进行个体鉴别．故将此检测及数据处理系统，命名为ＤＮＡ身份号码。     

串联质谱分析干血滤纸片中酰基肉碱质控

目的：串联质谱技术是近几年应用于临床检验的新技术，具有特异性强、灵敏度高，一次试验可检测数十种物质的优点。本文通过对近4年的质控结果进行分析，探讨影响检测结果的因素及应对措施。方法：美国CDC每年提供4批酰基肉碱质控干血滤纸片，酰基肉碱检测方法为取直径为3mm的质控干血滤纸片放入96孔聚丙烯板，经含酰基肉碱内标的甲醇萃取，盐酸正丁醇衍生后，进行串联质谱检测。分析本实验室质控结果与美国CDC检测结果的偏差及其他实验室质控结果（169个实验室的均值）与美国CDC检测结果的偏差之间的差异。结果：本实验室每次质控结果所有酰基肉碱均在美国CDC检测结果95％可信区间内，且每一批结果的临床评价与美国CDC质控临床评价完全一致。本实验室质控结果与美国CDC检测结果的偏差与其他实验室质控结果与美国CDC检测结果的偏差比较，无显著差异，丙酰基肉碱差异显著（Z=-2．638，P〈0．005），戊二酰基肉碱差异亦显著（Z=-2．482，P〈0．005）。结论：本实验室酰基肉碱质控结果，达到美国CDC的质控要求，丙酰基肉碱检测值偏高，其阳性判断切割值设定也相应增高，而戊二酰基肉碱检测值偏低，其阳性判断切割值设定也相应降低。     

不同机制大动脉粥样硬化型脑卒中基线特征和血管内治疗后结局比较

目的 本研究旨在比较颅内大血管伴/不伴同侧颈内动脉闭塞的大动脉粥样硬化型脑卒中患者基线特征以及行血管内治疗后结局的差异。方法 对DIRECT-MT亚组进行回顾性分析,以比较前循环大动脉粥样硬化（large-artery atherosclerosis,LAA）型卒中串联闭塞和颅内闭塞接受血管内治疗（endovascular treatment,EVT）的患者的基线特征和预后,分析不同机制学特征（动脉粥样硬化或动脉-动脉栓塞）对临床结局的影响。结果 LAA型卒中患者共108例,其中串联闭塞63例,颅内闭塞45例。颅内闭塞组患者高血压史率高于串联闭塞组（77.8% vs. 52.4%, P=0.007）。颅内闭塞组闭塞部位最常见于大脑中动脉M1段（88.6%）,而串联闭塞组颅内闭塞主要位于颈内动脉颅内段（49.2%）和大脑中动脉M1段（49.2%）（P＜0.001）。两组患者在年龄、性别、术前抗栓、他汀类药物的使用,卒中、房颤、吸烟史,基线mRS、NIHSS评分,是否静脉溶栓,侧枝循环,以及救治流程时间差异均无统计学意义（P均＞0.05）。90天mRS 0-2分的患者比例两组差异无统计学意义（53.3% vs. 41.9%, P=0.243）。颅内闭塞组术后成功再灌注率高于串联闭塞组（93.3% vs. 77.4%, P=0.026）,但术后24-72小时血管再通的比例前组低于后组（57.1% vs. 77.2%, P=0.034）。最终梗死体积,颅内闭塞组小于串联闭塞组（20.1 vs. 34.5, P=0.025）。术后NIHSS评分,90天EQ-5D-5L评分和BI指数等其他次要结局,两组间差异无统计学意义（P均＞0.05）。两组在90天内的死亡率,发生的无症状性和症状性颅内出血率,5-7天时在另外的血管区域新发脑梗死,以及新流域栓塞的患者百分比相似,差异无统计学意义（P均＞0.05）。结论 动脉粥样硬化导致的串联闭塞相较于孤立颅内闭塞,末次造影成功再灌注率较低,梗死体积更大,但术后24-72小时再通率更高,且神经功能良好预后率以及不良事件发生率均与颅内闭塞相仿。     

动脉粥样硬化遗传易感性与HUMARA多态性的相关性

目的 研究HUMARA基因多态性在陕西地区老年动脉粥样硬化（AS）人群中分布规律及其该位点与AS遗传易感性的关系。方法 应用多聚酶链反应（PCR）对96例老年AS患及92例非AS老年人HUMARA－STR（短串联重复序列short tandem repeats)位点进行多态性分析。结果 在HUMARA位点重复单位：CAG,对照群体片段大小在280－445bp之间,重复次数为N＝23－77,杂合度为83％,多态信息量（PIC）为0．76;AS人群中HUMARA位点,其片段大小在220－445bp之间,重复次数为N＝2－77,杂合度为89％,PIC为0．80。两组的基因频率分布比较无显性差异,但将男性的AS组与对照比较差异有显性;女性的AS组与对照比较差异无显性;正常组男性与女性比较差异无显性;AS组男性与女性比较差异有显性。结论 HUMARA基因多态位点可能作为男性易患动脉粥样硬化的遗传标记。     

Study on genetic polymorphisms of DCC gene VNTR in esophageal cancer

The abeted in Colo~ cancer gene (DCC) is re~ as a susceptibility gene in colol'eCtal cancer, whichis located on chlomesome 18qZI. 2. Ihactivation of thisgene may Play an i~ role dndng some Pimessessuch as ~ p~ssion and metastasis. With its ~allycloned, in lop, casinger et alllJ found that a vocablenumber tandem repeat (VNTR) is located wick an intwOf the DCC gene, its lepeat act is 2 hp,the core seqUence of (TA)n ~ numbers ~ 10 -- to tinies, whichis an ideal genetic rnalker. Esophageal…     

STR-PCR方法检测贵州小型香猪遗传变异性的研究

目的 准确分析贵州小型香猪种群遗传变异及近交程度。方法 采用１０对短串联重复序列（ＳＴＲ）引物,对贵州小型香猪个体进行ＰＣＲ检测。结果 在检测到的８８个有效等位基因型中,纯合基因型５０个,占５５．７％。个体平均杂合率为０．４０８１,位点平均杂合率为０．５５６２。结论 贵州小型香猪具有一定遗传稳定性,符合封闭群动物遗传学特征。     

Comprehensive genetic screening for vascular Ehlers–Danlos syndrome through an amplification-based next-generation sequencing system

Vascular Ehlers–Danlos syndrome (vEDS) is a hereditary connective tissue disorder (HCTD) characterized by arterial dissection/aneurysm/rupture, sigmoid colon rupture, or uterine rupture. Diagnosis is confirmed by detecting heterozygous variants in COL3A1. This is the largest Asian case series and the first to apply an amplification-based next-generation sequencing through custom panels of causative genes for HCTDs, including a specific method of evaluating copy number variations. Among 429 patients with suspected HCTDs analyzed, 101 were suspected to have vEDS, and 33 of them (32.4%) were found to have COL3A1 variants. Two patients with a clinical diagnosis of Loeys–Dietz syndrome and/or familial thoracic aortic aneurysm and dissection were also found to have COL3A1 variants. Twenty cases (57.1%) had missense variants leading to glycine (Gly) substitutions in the triple helical domain, one (2.9%) had a missense variant leading to non-Gly substitution in this domain, eight (22.9%) had splice site alterations, three (8.6%) had nonsense variants, two (5.7%) had in-frame deletions, and one (2.9%) had a multi-exon deletion, including two deceased patients analyzed with formalin-fixed and paraffin-embedded samples. This is a clinically useful system to detect a wide spectrum of variants from various types of samples.     

Validation of the STR system FES/FPS for forensic purposes in an Austrian population sample

The short tandem repeat system FES/FPS was amplified by the polymerase chain reaction (PCR) in 211 unrelated Austrians and analysed by horizontal, non-denaturing electrophoresis. The allele distribution was in Hardy-Weinberg equilibrium. No mutations were found in 25 families (50 meioses). The mean exclusion chance was 0.49, the discriminating power 0.86 and the heterozygosity rate 74.4%. Amplification could be achieved with as little as 100 pg of high molecular weight DNA, which could be reduced to 75 pg by using 32 instead of 30 cycles. By reamplifying 1 l for another 15 cycles, the threshold could be reduced to less than 20 pg. In a degradation experiment DNA extracted from bloodstains stored for up to 24 days in a moist chamber and DNA boiled for up to 18 min could be amplified.